AstraZeneca’s experimental drug, selumetinib, is the first targeted medication to show a significant clinical benefit for patients with melanoma of the eye (metastatic uveal melanoma), researchers from the Memorial Sloan-Kettering Cancer Center explain…
Category: News
Bausch + Lomb Receives FDA Approval of the Trulign Toric PCIOL
The Trulign Toric PCIOL (Bausch + Lomb), the first
toric IOL that provides astigmatic correction and
improved uncorrected near, intermediate, and distance
vision, has received FDA approval.
The FDA-approved indication of the Trulign is for
“primary implantation in the capsular bag of the eye
for the visual correct…
Large Study Tracked Racial Variations in Refractive Errors
Myopia and astigmatism are most prevalent in the
Chinese population, and hyperopia is most common
in the Hispanic population, according to a study in the
American Journal of emOphthalmology/em.sup1/sup
The study included participants in the Multi-Ethn…
Corneal Endothelial Loss Greater in Eyes With PXF After Cataract Surgery
Corneal endothelial cell loss and a transient
increase in central corneal thickness (CCT) were
greater after cataract surgery in eyes with pseudoexfoliation
(PXF) than in eyes without PXF, according
to a study in the emJournal of Cataract and Refractiv…
FDA Approves Aaren Scientific’s Aero Injection System
Aaren Scientific has been granted approval by the
FDA to sell the Aero Injection System for use with the
company’s EC-3 and EC-3 PAL aspheric three-piece
hydrophobic acrylic IOL, according to a company
news release.
The Aero Injection System is composed of the
R28 Model IOL Delivery System Injector and the Aero
Z…
Marguerite McDonald, MD, Recognized for Her Contributions to Ophthalmology
Marguerite McDonald, MD, was recently recognized
for her accomplishments in ophthalmology by CNN.
Her career and landmark contributions were profiled
in the Life’s Work series, which features “innovators
and pioneers who are making a difference in the
world of medicine.”
Specific milestones highlighted by CNN …
Effective Phaco Time Reduced in Eyes Pretreated With Femtosecond Laser
Pretreatment with a femtosecond laser significantly
reduced effective phacoemulsification time (EPT),
according to a study in emOphthalmology/em.sup1/sup
The prospective, interventional, consecutive casecontrolled
study included 201 eyes that underwen…
InSite Vision Starts Patient Enrollment in Confirmatory Phase 3 Clinical Trial of BromSite
Enrollment has begun in the confirmatory phase 3
clinical trial of BromSite (ISV-303; InSite Vision Inc.) for
the reduction of inflammation and pain after cataract
surgery.
ISV-303 combines a low dose (0.075%) of the nonsteroidal
antiinflammatory drug bromfenac with
InSite’s DuraSite drug delivery technology. This…
Laser-Related Programming Errors Avoidable in Refractive Surgery
The causes of laser-related programming errors in
refractive surgery are likely avoidable if preventive
measures such as strict adherence to patients’ verification
protocol or rigorous rechecking of treatment
parameters are implemented, according to a study in
the emJournal of Refractive Surgery/em.sup1/sup
In a m…
CXL Improved Morphological, Functional Parameters in Select Age Groups
Corneal collagen cross-linking (CXL) stabilized the
progression of ectatic disease 4 years postoperatively
in all age groups and improved the functional and
morphological parameters in select groups, with the
best results in patients between 18 and 39 …
Large Study Tracked Racial Variations in Refractive Errors
Myopia and astigmatism are most prevalent in the
Chinese population, and hyperopia is most common
in the Hispanic population, according to a study in the
emAmerican Journal of Ophthalmology/em.sup1/sup
The study included participants in the Multi-Ethn…
Valeant Pharmaceuticals Acquires Bausch + Lomb for $8.7 Billion
In a blockbuster deal that may reshape the eye care
landscape, Canadian drugmaker Valeant Pharmaceuticals
International Inc. announced it will acquire Bausch + Lomb
for $8.7 billion in cash.
Under the terms of the agreement, Valeant will pay
about $4….
Valeant Pharmaceuticals Acquires Bausch + Lomb for $8.7 Billion
In a blockbuster deal that may reshape the eye care
landscape, Canadian drugmaker Valeant Pharmaceuticals
International Inc. announced it will acquire Bausch + Lomb
for $8.7 billion in cash.
Under the terms of the agreement, Valeant will pay
about $4….
Marguerite McDonald, MD, Recognized for Her Contributions to Ophthalmology
Marguerite McDonald, MD, was recently recognized
for her accomplishments in ophthalmology by CNN.
Her career and landmark contributions were profiled
in the Life’s Work series, which features “innovators
and pioneers who are making a difference in the
world of medicine.”
Specific milestones highlighted by CNN …
Bausch + Lomb Receives FDA Approval of the Trulign Toric PCIOL
The Trulign Toric PCIOL (Bausch + Lomb), the first
toric IOL that provides astigmatic correction and
improved uncorrected near, intermediate, and distance
vision, has received FDA approval.
The FDA-approved indication of the Trulign is for
“primary implantation in the capsular bag of the eye
for the visual correct…
Effective Phaco Time Reduced in Eyes Pretreated With Femtosecond Laser
Pretreatment with a femtosecond laser significantly
reduced effective phacoemulsification time (EPT),
according to a study in emOphthalmology/em.sup1/sup
The prospective, interventional, consecutive casecontrolled
study included 201 eyes that underwen…
Corneal Endothelial Loss Greater in Eyes With PXF After Cataract Surgery
Corneal endothelial cell loss and a transient
increase in central corneal thickness (CCT) were
greater after cataract surgery in eyes with pseudoexfoliation
(PXF) than in eyes without PXF, according
to a study in the Journal of Cataract and Refractive
…
InSite Vision Starts Patient Enrollment in Confirmatory Phase 3 Clinical Trial of BromSite
Enrollment has begun in the confirmatory phase 3
clinical trial of BromSite (ISV-303; InSite Vision Inc.) for
the reduction of inflammation and pain after cataract
surgery.
ISV-303 combines a low dose (0.075%) of the nonsteroidal
antiinflammatory drug bromfenac with
InSite’s DuraSite drug delivery technology. This…
FDA Approves Aaren Scientific’s Aero Injection System
Aaren Scientific has been granted approval by the
FDA to sell the Aero Injection System for use with the
company’s EC-3 and EC-3 PAL aspheric three-piece
hydrophobic acrylic IOL, according to a company
news release.
The Aero Injection System is composed of the
R28 Model IOL Delivery System Injector and the Aero
Z…
Laser-Related Programming Errors Avoidable in Refractive Surgery
The causes of laser-related programming errors in
refractive surgery are likely avoidable if preventive
measures such as strict adherence to patients’ verification
protocol or rigorous rechecking of treatment
parameters are implemented, according to a study in
the emJournal of Refractive Surgery/em.sup1/sup
In a m…